Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors

Future Medicinal Chemistry

Volumn 1, Issue 8, 2009, Pages 1453-1466

  Duca, José S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AT 7519; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; FLAVOPIRIDOL; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PHA 848125; R 547; ROSCOVITINE; SCH 727965; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG DESIGN; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; CELL CYCLE; CYCLIN-DEPENDENT KINASE 2; DATABASES, PROTEIN; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEIN CONFORMATION;

EID: 77953407338     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.102     Document Type: Review

References (38)

1. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Ann. Rev. Cell Dev. Biol. 13(1), 261-291 (1997).
2. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13(12), 1501-1512 (1999).
3. Murray AW. Recycling the cell cycle cyclins revisited. Cell. 116(2), 221-234 (2004).
4. Morgan D. The Cell Cycle: Principles of Control (Primers in Biology). New Science Press Ltd, London, UK (2007).
5. Pucci B, Kasten M, Giordano A. Cell cycle and apoptosis. Neoplasia 2(4), 291-299 (2000).
6. Toogood PL. Progress toward the development of agents to modulate the cell cycle. Curr. Opin. Chem. Biol. 6(4), 472-478 (2002).
7. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1(4), 309-315 (2002).
8. Sawyers C. Targeted cancer therapy. Nature 432(7015), 294-297 (2004).
9. Garrett MD, Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur. J. Cancer (Oxf.) 35(14), 2010-2030 (1999).
10. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24(11), 1770-1783 (2006).
11. Thomas MP, McInnes C. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle. IDrugs 9(4), 273-278 (2006).
12. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9(3), 153-166 (2009).
13. Blagosklonny MV. Do cells need CDK2 and Bcr-Abl? Cell Death Differ. 11(3), 249-251 (2003).
14. Russo AA, Jeffrey PD, Pavletich NP. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nature Struc. Biol. 3(8), 696-700 (1996).
15. Berman HM, Battistuz T, Bhat TN et al. The protein data bank. Acta Crystallogr. D. Biol. Crystallogr. 58(1 Pt 6), 899-907 (2002).
16. Schulze-Gahmen U, Brandsen J, Jones HD et al. Multiple modes of ligand recognition: crystal structures of cyclindependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins 22(4), 378-391 (1995).
17. Schulze-Gahmen U, De Bondt HL, Kim SH. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. J. Med. Chem. 39(23), 4540-4546 (1996).
18. Knighton DR, Zheng JH, Ten Eyck LF et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253(5018), 407-414 (1991).
19. Lesburg CA, Duca JS. soaPDB: a web application for searching the Protein Data Bank, organizing results and receiving automatic email alerts. Nucleic Acids Res. 36, W252-W254 (2008).
20. DeLano W. The PyMOL molecular graphics system. The PyMOL Molecular Graphics System. (2002).
21. Molecular Operating Environment MOE. (Chemical Computing Group Inc., Montreal, H3A 2R7 Canada).
22. Deng Z, Chuaqui C, Singh J. Structural interaction fingerprint (SIFt): a novel method for analyzing 3D protein-ligand binding interactions. J. Med. Chem. 47(2), 337-344 (2004).
23. Durant JL, Leland BA, Henry DR, Nourse JG. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf. Comput. Sci. 42(6), 1273-1280 (2002).
24. Metrangolo P, Meyer F, Pilati T, Resnati G, Terraneo G. Halogen bonding in supramolecular chemistry. Angew. Chem. Int. Ed. Engl. 47(33), 6114-6127 (2008).
25. Fischmann TO, Hruza A, Duca JS et al. Structure-guided discovery of cyclindependent kinase inhibitors. Biopolymers 89(5), 372-379 (2008).
26. Bártová I, Koèa J, Otyepka M. Functional flexibility of human cyclin-dependent kinase-2 and its evolutionary conservation. Protein Sci. 17(1), 22-33 (2008).
27. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nature Struc. Mol. Biol. 15(10), 1109-1118. (2008)
28. IDdb3: Investigational Drugs Database 3. Current Drugs Ltd, London, UK.
29. Chu XJ, DePinto W, Bartkovitz D et al. Discovery of [4-amino-2-(1- methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. J. Med. Chem. 46(22), 6549-6560 (2006).
30. De Azevedo WF, Leclerc S, Meijer L et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243 (1-2), 518-526 (1997).
31. Krystof V, Cankar P, Frysov I et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J. Med. Chem. 49(22), 6500-6509 (2006).
32. Jeffrey PD, Russo AA, Polyak K et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376(6538), 313-320 (1995).
33. Richardson CM, Nunns CL, Williamson DS et al. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping. Bioorg. Med. Chem. Lett. 17(14), 3880-3885 (2007).
34. Bamborough P, Christopher JA, Cutler GJ et al. 5-(1H-Benzimidazol-1-yl)- 3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-e kinase. Bioorg. Med. Chem. Lett. 16(24), 6236-6240 (2006).
35. Bettayeb K, Tirado OM, Marionneau- Lambot S et al. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res. 67(17), 8325-8334 (2007).
36. Kornev AP, Haste NM, Taylor SS, Eyck LF. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl Acad. Sci. USA 103(47), 17783 (2006).
37. Kostich M, English J, Madison V et al. Human members of the eukaryotic protein kinase family. Genome Biol. 3(9), RESEARCH0043 (2002).
38. Orzaez M, Gortat A, Mondragon L, Bachs O, Perez-Paya E. ATP-noncompetitive inhibitors of CDK-cyclin complexes. ChemMedChem. 4(1), 19-24 (2009).